Document is current
Any future updates will be listed below
-
Authors
Ma, Qiuling
Wei, Runhong
Wang, Qingming
Jiang, Songfu
Wu, Yi
Min, Chao
Guo, Shufang
Zhang, Yu
Sun, Xiaohong
Wu, Haigang
Sun, Xuedong
Xiang, Fang
Xiao, Mingxing
Cheng, Zhi
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04303520 at ClinicalTrials.govDocuments that mention this clinical trial
A bi-specific CAR-T cell therapy targeting CD19 and CD22 in relapsed or refractory B-ALL
https://doi.org/10.1007/s10238-025-01637-8
-
Funding
Funding for this research was provided by:
Natural Science Foundation of Henan Province of China (222300420487, 222300420487, 222300420487)
The Scientific and technological project in Henan Province of China (222102310353, 222102310353, 222102310353)
Government-funded Project on Traditional Chinese Medicine in Henan Province of China (2024ZY1010, 2024ZY1010, 2024ZY1010)
- License Information
-
More Information
Article History
Received: 5 January 2025
Accepted: 14 March 2025
First Online: 28 July 2025
Declarations
:
: Author Xuedong Sun, Fang Xiang, and Mingxing Xiao are employed by Hrain Biotechnology Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
: This investigation was approved by the ethics committee of Henan Province Hospital of Traditional Chinese Medicine (Second Affiliated Hospital of Henan University of Chinese Medicine) with ID of the ethics approval: 2016010508.
: Not applicable.
